Novocure announced the FDA treated its Optune Lua wearable device for treating metastatic non-small cell lung cancer.
Optune Lua uses tumor-treating fields (TTFields) to exert physical forces on the electrically charged components of dividing cancer cells. This results in cell death.
Related: CMR Surgical wins FDA clearance for next-gen Versius Surgical System
The FDA approved the device for concurrent use with PD-1/PD-L1 inhibitors or docetaxel to treat mNSCLC patients who have progressed on or after a platinum-based regimen.
“Novocure is committed to extending survival in some of the most aggressive and difficult to treat cancers. The approval of Optune Lua brings a new and urgently needed option for people with metastatic NSCLC who have progressed while on or after platinum-based chemotherapy,” said Asaf Danziger, CEO, Novocure. “We are grateful to the patients, caregivers, investigators and healthcare providers who supported the clinical trials that led to this approval.”
